Clinical Trial Update: Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study [Phase 3]

View source ↗

Summary

A Phase 3 randomized study evaluating olanzapine plus fosaprepitant with standard antiemetic therapy for preventing chemotherapy-induced nausea and vomiting in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE)
• olanzapine (olanzapine)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy | Phase 3 | Status: UNKNOWN